1Dougados M, B6hier JM, Jolchine I,et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory dnlg. Arthritis Rheum. 2001,44 : 180-185.
2Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis,2011,70:896-904.
3Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford) ,2010,49:536-541.
4Wanders AI Heijde Dv, Landew6 R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical triM. Arthritis Rheum ,2005,52 : 1756-1765.
6Straube S, Trainer MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol,2009,9:41.
8Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults : results of a US consensus panel of experts. Arch Intern Med, 2003,163:2716-2724.
10Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/ epidemiological studies in axial spondyloarthritis. Ann Rheum Dis,2011,70:249-251.
二级参考文献41
1BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[ J]. N Engl J Med, 2000, 343(21 ) :1520 - 1528.
2SCHNITZER TJ, BURMESTER GR, MYSLER E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial[ J]. Lancet, 2004, 364(9435 ) :665 - 674.
3SILVERSTEIN FE, FAICH G, GOLDSTEIN JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS stud- y: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[ J]. JAMA, 2000, 284 (10) : 1247 - 1255.
4LAINE L, CURTIS SP, CRYER B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [ J ]. Lancet, 2007, 369 (9560) :465 - 473.
5BRESALIER RS, SANDLER RS, QUAN H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma che- moprevention trial[ J ]. N Engl J Med, 2005, 352 (11 ) :1092 - 1102.
6BERTAGNOLLI MM, EAGLE C J, ZAUBER AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas [ J ]. N Engl J Med, 2006, 355 ( 9 ) :873 - 884.
7KEARNEY PM, BAIGENT C, GODWIN J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials [ J]. BMJ, 2006, 332 (7553) : 1302 - 1308.
8MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296(13): 1633 -1644.
9HINZ B, RENNER B, BRUNE K. Drug insight: cyclo-oxygenase-2 inhibitors a critical appraisal [ J ]. Nat Clin Pract Rheumatol, 2007, 3 (10) :552 - 560.
10ZANCHETTI A, HANSSON L, DAHLOF B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group[ J]. J Hypertens, 2001, 19 (6) :1149 - 1159.
